Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Scandinavian Journal of Rheumatology

• Publication date

  2006-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/03009740500474578PMID 16641043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

  2005cited by this paper
• Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.

  2005cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Inhibition of Tumor Necrosis Factor-&agr; Reduces Atherosclerosis in Apolipoprotein E Knockout Mice

  2004cited by this paper
• High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease

  2004cited by this paper
• Accelerated atherosclerosis in inflammatory rheumatic diseases

  2004cited by this paper
• Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

  2004cited by this paper
• Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

  2003cited by this paper
• Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.

  2002cited by this paper
• Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?

  2002cited by this paper
• Multiple roles for tumor necrosis factor-α and lymphotoxin α/β in immunity and autoimmunity

  2002influential reference
• The role of TNF alpha in adipocyte metabolism.

  1999cited by this paper
• Epidemiologic aspects of lipid abnormalities.

  1998cited by this paper
• Effects of an Engineered Human Anti–TNF-α Antibody (CDP571) on Insulin Sensitivity and Glycemic Control in Patients With NIDDM

  1996cited by this paper
• Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica.

  1995cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• Bronchial hyperresponsiveness to methacholine in patients with primary Sjögren's syndrome.

  1991cited by this paper
• Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis.

  1991cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper

• TNF inhibitors associated with cardiovascular diseases and cardiometabolic risk factors: a Mendelian randomization study.

  2023cites this paper
• Correlation between percentage of fat mass and level of disease activity in rheumatoid arthritis

  2022cites this paper
• Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights

  2021cites this paper
• Improvements in High-Density Lipoprotein Quantity and Quality Contribute to the Cardiovascular Benefits by Anti-tumor Necrosis Factor Therapies in Rheumatoid Arthritis: A Systemic Review and Meta-Analysis

  2021cites this paper
• Comparisons of the Incidence and Critical Risk Factors of Metabolic Syndrome in Patients With a Rheumatic Disease or Gout

  2019cites this paper
• Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly?

  2018cites this paper
• The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review

  2018cites this paper
• Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis

  2018cites this paper
• Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China.

  2017cites this paper
• Cardiovascular disease in rheumatoid arthritis: risk profile and risk prediction

  2017influential citation
• A psoriatic arthritis patient who developed hypertriglyceridemia while receiving adalimumab treatment

  2017cites this paper
• IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis

  2017cites this paper
• Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism

  2017cites this paper
• Clinical efficacy : pharmacokinetics and phase I-II , II , and III trials Pharmacokinetics and phase I-II trials

  2017cites this paper
• Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease.

  2017cites this paper
• Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease.

  2017cites this paper
• Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two‐Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial

  2016cites this paper
• Abatacept Improves Whole-Body Insulin Sensitivity in Rheumatoid Arthritis

  2015cites this paper
• Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: A meta-analysis of prospective studies

  2014cites this paper
• From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

  2014cites this paper
• Is it safe to use TNF-α blockers for systemic inflammatory disease in patients with heart failure? Importance of dosage and receptor specificity.

  2013cites this paper
• Rheumatoid arthritis and cardiovascular disease: an update on treatment issues

  2013cites this paper
• Lipid associated biomarkers in patients with systemic lupus erythematosus and rheumatoid arthritis

  2013cites this paper
• Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

  2013cites this paper
• Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation

  2013cites this paper
• A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

  2012cites this paper
• Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals

  2012influential citation
• Addressing cardiovascular risk factors and therapy effects in rheumatoid arthritis: implications for atherosclerosis and cardiovascular disease

  2012cites this paper
• Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

  2012cites this paper
• Psoriasis and metabolic syndrome

  2012cites this paper
• Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti–tumor necrosis factor therapy

  2012cites this paper
• Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis

  2012cites this paper
• Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis

  2012cites this paper
• Tocilizumab for the treatment of rheumatoid arthritis

  2012cites this paper
• A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

  2012cites this paper
• Aspects on Inflammation and Cardiovascular Comorbidity in Rheumatoid Arthritis

  2012cites this paper
• La polyarthrite rhumatoïde : une maladie cardiovasculaire ?

  2012cites this paper
• The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients

  2012cites this paper
• El factor de necrosis tumoral-α, la resistencia a la insulina, el metabolismo de lipoproteínas y la obesidad en humanos

  2012cites this paper
• Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.

  2012cites this paper
• Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program

  2011cites this paper
• Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis.

  2011cites this paper
• Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation.

  2011cites this paper
• Urinary tract infection : a serious health problem in old women

  2011cites this paper
• Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review.

  2011cites this paper
• Treatment with Tumor Necrosis Factor Antagonists and Their Possible Effects on Morbidity and Mortality in Psoriasis Patients

  2011cites this paper
• Unresolved issues in biologic therapy for rheumatoid arthritis

  2011cites this paper
• Integrated safety in tocilizumab clinical trials

  2011cites this paper
• A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis

  2010influential citation
• Risque cardiovasculaire associé à la corticothérapie à faible dose dans la polyarthrite rhumatoïde: revue de la littérature

  2010cites this paper
• Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

  2010cites this paper
• Tocilizumab - a new step in rheumatoid arthritis treatment.

  2010cites this paper
• Can early treatment with biologicals modify the natural history of comorbidities?

  2010cites this paper
• Biologika und kardiovaskuläres Risiko

  2010cites this paper
• Increased Prevalence of the Metabolic Syndrome in Patients with Psoriatic Arthritis

  2010cites this paper
• Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study

  2010cites this paper
• Comments on the original article by Soubrier et al. "Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis".

  2009cites this paper
• TNF‐α, a potent lipid metabolism regulator

  2009cites this paper
• therogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve atients with early rheumatoid arthritis

  2009cites this paper
• Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

  2009cites this paper
• Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors.

  2009cites this paper
• Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?

  2009cites this paper
• Inhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis

  2009cites this paper
• Effects of tumor necrosis factor‐α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis

  2009cites this paper
• Commentaires concernant l’article original de Soubrier et al. « Effets de la thérapie anti-TNF sur le profil lipidique chez des patients atteints de polyarthrite rhumatoïde »

  2009cites this paper
• Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

  2009cites this paper
• Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.

  2009influential citation
• Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease

  2009cites this paper
• A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.

  2009cites this paper
• [Inhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis].

  2009cites this paper
• La inhibición de la interleucina-6, una nueva opción terapéutica en la artritis reumatoide

  2009cites this paper
• Atherosclerosis: a complex interplay of inflammatory processes

  2009cites this paper
• Effets de la thérapie anti-TNF sur le profil lipidique chez des patients atteints de polyarthrite rhumatoïde

  2008cites this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cites this paper
• Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study

  2008cites this paper
• Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis.

  2008cites this paper
• Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus

  2008cites this paper
• Anti-tumour necrosis factor agents and lipid profile: a class effect?

  2008cites this paper
• Rheumatoid arthritis and cardiovascular disease

  2008cites this paper
• Psoriasis comorbidities

  2008cites this paper
• Tolérance des glucocorticoïdes dans la polyarthrite rhumatoïde : élaboration de recommandations pour la pratique clinique, à partir d’une analyse systématique de la littérature et de l’opinion d’experts

  2008cites this paper
• Relapse of sarcoidosis upon treatment with etanercept

  2008cites this paper
• by EULAR and ASAS (ASsessment in Ankylosing Spondylitis

  2008cites this paper
• Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review

  2007cites this paper
• Infliximab in the treatment of psoriasis in patients previously treated with etanercept.

  2007cites this paper
• Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins.

  2007cites this paper
• Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis

  2007cites this paper
• Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis

  2007cites this paper
• Serum protein profile of rheumatoid arthritis treated with anti-TNF therapy (infliximab).

  2007cites this paper
• Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.

  2007cites this paper
• Insulin resistance in patients with rheumatoid arthritis: effect of anti‐TNFα therapy

  2007cites this paper
• Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.

  2007cites this paper
• Atherogenic lipid profiles and its management in patients with rheumatoid arthritis

  2007cites this paper
• Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.

  2007cites this paper
• Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.

  2007cites this paper
• Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis

  2007cites this paper
• Biologics: Targets and Therapy Dovepress Effects of 6 Months of Abatacept Treatment on Aortic Stiffness in Patients with Rheumatoid Arthritis

  year unknowncites this paper
• Urinary Tract Infection ‐ a Serious Health Problem in Old Women Table of Contents Svensk Sammanfattning (summary in Swedish)

  year unknowncites this paper